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Drug discovery and development
The authors of this letter, a pre-clinical scientist, a translational
researcher, and a clinical trialist, just returned back from a particularly
interesting annual meeting of the Heart Failure Society of the ESC in
the gorgeous city of Lisbon. In the program, ample space was also
dedicated to drugs for the treatment of acute heart failure (AHF) and
large audiences enjoyed lectures, discussions, posters, industry-
sponsored satellites and expert panels focused on the past, present
and future of diuretics, vasodilators and inotropes. It's indeed a hot
topic, as it has been for many years.
We three have been active in our respective research ﬁelds for at
least two decades each and reacted, again, to a disturbing phenom-
enon which in waves appears in the scientiﬁc community: the paean
for “all-old-failed-all-new-will-succeed” pervading all discussions, being
them focused on molecular targets or on clinical trials.
Taking a helicopter view over two decades or preclinical,
translational and clinical research, and having seen several molecules
coming into use, we would like to recommend caution to our
colleagues. Our message can be summarized in two points: (I) all
old did not fail but possibly reached its proper niche of use, and (II) all
new will not possibly succeed if it will not strive to arrive to its proper
niche of use.
The conundrum is in fact in the deﬁnition of “failure”. It is in fact
proper to speak about “failure” of a drug when it does not reach the
market for lack of regulatory approval on the basis of safety and
efﬁcacy reasons, and, to some extent, it is too understandable when
industry deﬁnes “failure” a drug which does not pay back its
investment costs as planned. It is, however, less understandable
when clinicians deﬁne “failure” a drug which misses some end points
in clinical regulatory trials on populations large enough but often very
heterogeneous. Just as an example, limiting our discussion on
inotropes and inodilators, molecules such as dobutamine, dopamine,
digoxine, amrinone, milrinone, enoximone, and the most recent
levosimendan have indeed been all taken in use, albeit often not in
general use, after more or less broad and successful development and
regulatory phases.
At the horizon new targets and molecules are appearing, and seem
to be as promising as the old have been in the corresponding stage of
their lives. Activators of myosin or other targets in the contractile
apparatus [1] are currently described with vivid colors by often
overenthusiastic scientists. The scientiﬁc community sees a dichot-
omy between old drugs and promising molecules, and often a new
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Fig. 1. Hazard ratio for all-cause mortality (levosimendan vs. placebo on top of standard
of care) at 14 days in the REVIVE-II study as function of the systolic blood pressure at
randomization [8] (with permission).
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promise become suddenly an old failure: like in the description of père
Champmathieu in Viktor Hugo's Les Miserables: “Quand j'étais enfant,
on m'appelait Petit, maintenant on m'appelle Vieux”. We heard key
opinion leaders at the annual congress describing the current
inotropes and inodilators as “old failures” despite used by a broad
segment of colleagues who do not like to feel passé just because they
collected good experiences in daily practice with those treatments in
acute settings.
Dobutamine, milrinone, and levosimendan did indeed ﬁnd their
own place in therapy, as demonstrated by recent surveys on the use of
inotrope and inodilator in general practice [2,3] and deserve proper
consideration also in the light of recent studies (smaller but more
focused) which demonstrate their beneﬁts in some population
segment and in some stages of the disease. Let's remember that
acute (decompensated or de novo) heart failure has a complex
deﬁnition and presents a variety of etiologies, symptoms and
manifestations [4]. In some segments, drugs as levosimendan are
doing great [5]. Such drugs cannot be deﬁned as a panacea for AHF, but
surely not as “failed” drugs. According to this, we recommend
Industries who develop new drug for AHF to focus on smaller but
better deﬁned segment. The dream for a good-for-all drug which could
complement diuretics and vasodilators in the treatment of AHF is
alluring and could bring the newcomers to a failure, in the more strict
regulatory deﬁnition.
Industry, in our opinion, should not be seeking for block busters in
the complex ﬁeld of AHF, and the scientiﬁc community (or at least the
loud part of it which gives lecture at the annual congresses) should
also realistically recognize the merit of what is on the market before
treating it as “old and failed” in waiting for the “new-and-promising”.
This draconian attitude could generate the never ending and
frustrating feeling well described by Beckett in his “Waiting for
Godot”, and create a bigger fracture between current use and ideal-
guidelines.
At this regard we wish also to point out how the positioning of
inodilators in the recent Heart Failure guidelines, compared to the
previous, is misleading, in some cases dangerously. As an example the
vasodilator and inotrope levosimendan, whichwas in the 2005 [4] and
2008 version of the guidelines [6] duly recommended for patients
with baseline pressure over 100 mm Hg is now recommended for
patients with pressures under 85 mm Hg [7]. A paramount change is
not justiﬁed by any new study or publication in this sense. On the
contrary, the newly published REVIVE study [8] (which data were
indeed known to the scientiﬁc community and to the regulatory
authorities from November 2005) [9,10] corroborates the use of this
drug to patients with higher pressure, as seen also in the speciﬁcation
for the use of the drug (see Fig. 1) [8].
We are particularly excited by the decision of the newly renewed
Translational Committee of the Heart Failure Association to focus
on sarcomere and/or excitation–contraction coupling in one of the
upcoming workshops: we hope that the discussionwill not be spoiled
by confounding “non-blockbuster” drugs with “failed” target mole-
cules. A target in fact is not a drug and a drug has very often several
targets and several effects which can be in different forms proven in
clinical trials. We conclude with a hope that the ﬁeld of AHF drug
therapy will not become what Yeats described as “No country for old
men…”: we wish in fact to expect the new without throwing the old.
The “new” in fact could become “old” in an eyeblink.
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